Ivabradine in the Acute Management of Cardiogenic Shock

Summary

Brief Summary: The IVASHOCK trial investigates whether ivabradine can achieve at least one-class improvement in SCAI cardiogenic shock classification compared to placebo, and evaluates its safety profile in patients with cardiogenic shock (CS). Primary Objectives: 1. To determine whether ivabradine improves SCAI shock classification by at least one class from baseline within 72 hours compared to placebo 2. To assess whether ivabradine facilitates earlier weaning from vasoactive and inotropic support compared to placebo Safety Endpoints: Adverse events monitored include: sinus node dysfunction, new-onset atrial fibrillation or atrial flutter, atrioventricular block, drug-related hypotension, and ventricular arrhythmia. Participant Schedule: Participants will receive ivabradine or placebo orally every 12 hours for 3 days. Hemodynamic and metabolic assessments will include: Arterial pH, central venous oxygen saturation (ScvO2), and serum lactate - every 6 hours on Day 1, then every 8 hours on Days 2 and 3 Heart rate, mean arterial pressure (MAP), vasoactive/inotropic support dose, and urine output - measured on the same timeline

Eligibility

Inclusion Criteria:

* Patients aged 18-75 years diagnosed with STEMI complicated by cardiogenic shock (CS) as defined by SCAI shock classification \> C:

Signs of Hypoperfusion including:

1. SBP \<90 OR MAP \<60 OR \>30 mmHg drop from baseline AND drugs/device used to maintain BP above these targets
2. Cold, clammy extremities
3. Urine output \<30 mL/h
4. pulmonary congestion (either crackles, congestion in chest X-ray or B-lines in lung US)
5. Mixed venous oxygen saturation ≤ 65%

   * Severe Left ventricular (LV) dysfunction or right ventricular (RV) infarction
   * Heart rate (HR) ≥ 100 bpm (Sinus Rhythm) in whom beta-blocker therapy cannot be initiated, including: On inotropic or vasopressor support, Requiring an intra-aortic balloon pump (IABP), With Killip class III or IV, Requiring BiPAP or mechanical ventilation

Exclusion Criteria:

* Age \> 75 years
* CPR \> 12 mints
* Atrial fibrillation
* Complete Heart Block
* Heart rate of \< 100 bpm
* End stage Renal Disease
* Extensive comorbidities; Prior CVA, Malignancy, Pregnancy or Ongoing Participation in Other Trials

Conditions2

Interventions2

Related trials

• "The Effect of Memantine on the Prevention and Amelioration of Paclitaxel-induced Toxicity in Breast Cancer Patients" — Ain Shams University
• Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy — Chinese University of Hong Kong
• Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients — National Cancer Center, Korea
• Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion — University of Cape Town
• Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy — Niels Fristrup
• Measurement of the Hippocampal Theta Rhythm From the Outer Ear Canal — University of Manitoba
• Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose — Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
• Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity — Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Browse More Trials